Prothena Co. plc (NASDAQ:PRTA - Free Report) - Research analysts at Leerink Partnrs lowered their FY2028 earnings estimates for Prothena in a research report issued to clients and investors on Wednesday, May 8th. Leerink Partnrs analyst R. Li now anticipates that the biotechnology company will post earnings per share of $5.80 for the year, down from their prior forecast of $5.85. The consensus estimate for Prothena's current full-year earnings is ($4.88) per share.
Several other equities analysts also recently issued reports on PRTA. Royal Bank of Canada dropped their price target on shares of Prothena from $36.00 to $35.00 and set a "sector perform" rating for the company in a research note on Friday, February 16th. Bank of America reaffirmed a "neutral" rating and set a $38.00 price target (down previously from $68.00) on shares of Prothena in a research note on Tuesday, January 30th. Cantor Fitzgerald reissued an "overweight" rating on shares of Prothena in a research note on Wednesday, April 10th. Oppenheimer lowered their target price on shares of Prothena from $98.00 to $80.00 and set an "outperform" rating for the company in a research note on Tuesday, February 20th. Finally, StockNews.com downgraded shares of Prothena from a "hold" rating to a "sell" rating in a research note on Monday, February 19th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $67.00.
Read Our Latest Research Report on PRTA
Prothena Stock Down 3.0 %
Shares of PRTA stock traded down $0.66 during trading hours on Friday, hitting $21.34. 454,300 shares of the company's stock traded hands, compared to its average volume of 512,957. The stock's 50 day simple moving average is $24.05 and its 200 day simple moving average is $30.30. The stock has a market cap of $1.15 billion, a PE ratio of -7.62 and a beta of 0.30. Prothena has a 12 month low of $19.65 and a 12 month high of $77.13.
Prothena (NASDAQ:PRTA - Get Free Report) last issued its earnings results on Wednesday, May 8th. The biotechnology company reported ($1.34) earnings per share for the quarter, missing analysts' consensus estimates of ($1.21) by ($0.13). Prothena had a negative net margin of 160.91% and a negative return on equity of 24.84%. The company had revenue of $0.05 million during the quarter, compared to analyst estimates of $3.75 million. During the same quarter in the prior year, the business earned ($0.89) EPS.
Institutional Trading of Prothena
Several hedge funds and other institutional investors have recently modified their holdings of the business. SG Americas Securities LLC grew its stake in Prothena by 46.9% in the 4th quarter. SG Americas Securities LLC now owns 135,857 shares of the biotechnology company's stock worth $4,937,000 after buying an additional 43,363 shares in the last quarter. Trexquant Investment LP purchased a new position in Prothena in the 3rd quarter worth approximately $2,743,000. Mariner LLC grew its stake in Prothena by 24.3% in the 3rd quarter. Mariner LLC now owns 167,932 shares of the biotechnology company's stock worth $8,103,000 after buying an additional 32,870 shares in the last quarter. Qube Research & Technologies Ltd boosted its stake in shares of Prothena by 104.5% in the 3rd quarter. Qube Research & Technologies Ltd now owns 84,653 shares of the biotechnology company's stock valued at $4,085,000 after purchasing an additional 43,256 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Prothena by 99.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,375 shares of the biotechnology company's stock valued at $66,000 after purchasing an additional 684 shares in the last quarter. Institutional investors own 97.08% of the company's stock.
About Prothena
(
Get Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Further Reading
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
